Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares

Reuters12-10

Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares

Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590373878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590373878","market":"fut","top_or_hot":-1,"title":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 08:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6WJy9c:1","article_id":"2590373878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590373878","pubTimestamp":1765326446,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein  monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 , which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1147":"投资银行业与经纪业","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01911":"华兴资本控股","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","01801":"信达生物","BK1589":"北水核心资产"},"translate_title":"信达生物为抗IL-1RAP抗体治疗痛风发作的1期试验中的首例参与者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n    \n\nInnovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590373878","isCrawlerRequest":true}